# A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation

> **NCT05357690** · PHASE2,PHASE3 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 220 (estimated)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **PROCEDURE:** Stellate ganglion block
- **DRUG:** Bupivacaine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05357690
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-19
- **Primary completion:** 2026-04
- **Final completion:** 2026-12
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05357690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05357690, "A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05357690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*